Credit Suisse’s Ginkgo Bioworks DNA Stock Holding History

Credit Suisse’s Portfolio DNA Stock Details DNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1.33M	Sell	28,648 -1,483	-5%	-$76.8K	﹤0.01%	2102
2023 Q4	$2.04M	Buy	30,131 +1,972	+7%	+$121K	﹤0.01%	1870
2023 Q3	$2.04M	Buy	28,159 +2,550	+10%	+$204K	﹤0.01%	1827
2023 Q2	$1.91M	Sell	25,609 -3,371	-12%	-$200K	﹤0.01%	1945
2023 Q1	$1.54M	Buy	28,980 +6,554	+29%	+$415K	﹤0.01%	2032
2022 Q4	$1.52M	Buy	22,426 +3,362	+18%	+$309K	﹤0.01%	2044
2022 Q3	$2.38M	Buy	19,064 +1,529	+9%	+$182K	﹤0.01%	1749
2022 Q2	$1.67M	Buy	17,535 +11,369	+184%	+$1.39M	﹤0.01%	2040
2022 Q1	$994K	Buy	6,166 +2,743	+80%	+$534K	﹤0.01%	2552
2021 Q4	$1.14M	Buy	+3,423	New	+$1.63M	﹤0.01%	3224

Other funds holding DNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACG

Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's DNA Position: Q1 2024 in Review

Credit Suisse reduced its Ginkgo Bioworks (DNA) stake by 4.9% in Q1 2024, selling an estimated $76.8K and leaving 28,648 shares worth $1.33M. The position accounts for ﹤0.01% of the portfolio, ranked #2102.

Credit Suisse first reported a position in DNA in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.38M in Q3 2022. 342 funds tracked by Wall St. Rank hold DNA as of Q1 2024.

Credit Suisse held 28,648 shares of Ginkgo Bioworks worth $1.33M as of Q1 2024.
Credit Suisse sold 1,483 Ginkgo Bioworks shares in Q1 2024, an estimated $76.8K.
Ginkgo Bioworks made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2102 holding.
Credit Suisse first reported a position in Ginkgo Bioworks in Q4 2021 and has held it in 10 quarters since.
Credit Suisse's Ginkgo Bioworks position peaked at $2.38M in Q3 2022.
342 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.